Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Treatment with interferon beta has been shown to help patients with established multiple sclerosis, but it is not known whether initiating treatment at the time of a first clinical demyelinating event is of value. METHODS: We conducted a randomized, double-blind trial of 383 patients who had a first acute clinical demyelinating event (optic neuritis, incomplete transverse myelitis, or brain-stem or cerebellar syndrome) and evidence of prior subclinical demyelination on magnetic resonance imaging (MRI) of the brain. After initial treatment with corticosteroids, 193 patients were randomly assigned to receive weekly intramuscular injections of 30 microg of interferon beta-1a and 190 were assigned to receive weekly injections of placebo. The study end points were the development of clinically definite multiple sclerosis and changes in findings on MRI of the brain. The trial was stopped after a preplanned interim efficacy analysis. RESULTS: During three years of follow-up, the cumulative probability of the development of clinically definite multiple sclerosis was significantly lower in the interferon beta-1a group than in the placebo group (rate ratio, 0.56; 95 percent confidence interval, 0.38 to 0.81; P=0.002). As compared with the patients in the placebo group, patients in the interferon beta-1a group had a relative reduction in the volume of brain lesions (P<0.001), fewer new or enlarging lesions (P<0.001), and fewer gadolinium-enhancing lesions (P<0.001) at 18 months. CONCLUSIONS: Initiating treatment with interferon beta-1a at the time of a first demyelinating event is beneficial for patients with brain lesions on MRI that indicate a high risk of clinically definite multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Self-citationThe IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Minimization: A new method of assigning patients to treatment and control groups
Taves, D. R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974155443 · Cited by 891
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
Rudick, R. A., Fisher, E., Lee, J.-C., Simon, J., Jacobs, L., & the Multiple Sclerosis Collaborative Research Group (1999) · Neurology · doi:10.1212/wnl.53.8.1698 · Cited by 736
Self-citationThe Clinical Profile of Optic Neuritis: Experience of the Optic Neuritis Treatment Trial
(1991) · Archives of Ophthalmology · doi:10.1001/archopht.1991.01080120057025 · Cited by 600
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up
O'Riordan, J. (1998) · Brain · doi:10.1093/brain/121.3.495 · Cited by 484
ORMEROD, I. E. C., MILLER, D. H., McDONALD, W. I., BOULAY, E. P. G. H. D., RUDGE, P., KENDALL, B. E., MOSELEY, I. F., JOHNSON, G., TOFTS, P. S., HALLIDAY, A. M., et al. (1987) · Brain · doi:10.1093/brain/110.6.1579 · Cited by 468
Morrissey, S. P., Miller, D. H., Kendall, B. E., Kingsley, D. P. E., Kelly, M. A., Francis, D. A., MacManus, D. G., & McDonald, W. I. (1993) · Brain · doi:10.1093/brain/116.1.135 · Cited by 360
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
Rudick, R. A., Simonian, N. A., Alam, J. A., Campion, M., Scaramucci, J. O., Jones, W., Coats, M. E., Goodkin, D. E., Weinstock-Guttman, B., Herndon, R. M., et al. (1998) · Neurology · doi:10.1212/wnl.50.5.1266 · Cited by 333
Self-citationMagnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis
Simon, J. H., Jacobs, L. D., Campion, M., Wende, K., Simonian, N., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410430114 · Cited by 330
Self-citationThe 5-year risk of MS after optic neuritis: Experience of the Optic Neuritis Treatment Trial
Optic Neuritis Study Group* (1997) · Neurology · doi:10.1212/wnl.49.5.1404 · Cited by 298
The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis
Fazekas, F., Barkhof, F., Filippi, M., Grossman, R. I., Li, D. K. B., McDonald, W. I., McFarland, H. F., Paty, D. W., Simon, J. H., Wolinsky, J. S., et al. (1999) · Neurology · doi:10.1212/wnl.53.3.448 · Cited by 287
Self-citationQuantitative MRI in patients with clinically isolated syndromes suggestive of demyelination
Sailer, M., O’Riordan, J. I., Thompson, A. J., Kingsley, D. P., MacManus, D. G., McDonald, W. I., & Miller, D. H. (1999) · Neurology · doi:10.1212/wnl.52.3.599 · Cited by 133
Jacobs, L. D., Kaba, S. E., Miller, C., Priore, R. L., & Brownscheidle, C. M. (1997) · Annals of Neurology · doi:10.1002/ana.410410315 · Cited by 90
Self-citation
Cited by
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Self-citationDefining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Metadata
- Authors
- Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2000-09-28
- Volume
- 343
- Issue
- 13
- Pages
- 898-904
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2313649737
- Cited by
- 1,501
- References
- 17
- FWCI
- 45.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.